The University of Nevada, Reno School of Medicine

Starting the Conversation: Optimizing Psoriatic Disease Outcomes With GLP-1 Receptor Agonists

PA-C, MPAS

Discuss the mechanistic rationale of combining interleukin (IL)-17 biologics and glucagon-like peptide (GLP)-1 receptor agonists in psoriatic disease management for patients with obesity, including disease control and weight loss

Review the latest clinical efficacy and safety data surrounding the use of combination regimens using biologics and GLP-1 receptor agonists for the treatment of patients with both psoriatic disease and overweight or obesity

Design combination treatment regimens using biologics and GLP-1 receptor agonists for patients with both psoriatic disease and comorbid overweight or obesity

Identify strategies for integrating GLP-1 receptor agonists into dermatology practice, considering patient support programs to improve access and adherence

Psoriasis is a chronic, immune-mediated inflammatory disease characterized by dysregulated IL-23/IL-17 axis signaling and keratinocyte hyperproliferation, resulting in well-demarcated erythematous plaques with silvery scale. Beyond cutaneous involvement, psoriasis has been linked to systemic inflammation contributing to increased risk of cardiometabolic and other inflammatory comorbidities.

This hub gathers the evidence, expert perspective, and practical insight shaping how psoriasis is understood and treated today, connecting advances in targeted therapy with the everyday decisions required to manage chronic inflammation and systemic risk.

PANP25: Starting the Conversation: Optimizing Psoriatic Disease Outcomes With GLP-1 Receptor Agonists

About

Learning Objectives

Intended Audience

Faculty

Accreditation Statement

Credit Designation Statement

Disclosures